Since extended treatment with the HER2 inhibitors results in the suppression of HER2 expression, we questioned whether prolonged treatment with an HER2 inhibitor lapatinib sensitizes HER2+ breast cancer lines to combined TAM/Met and CDK4/6 inhibition. Here, ERBB2 is linked to breast cancer.